| The cost effectiveness of human papillomavirus vaccines: a systematic review K Seto, F Marra, A Raymakers, CA Marra Drugs 72, 715-743, 2012 | 124 | 2012 |
| Comparison of outpatient and home‐based exercise training programmes for COPD: a systematic review and meta‐analysis F Wuytack, D Devane, E Stovold, M McDonnell, M Casey, TJ McDonnell, ... Respirology 23 (3), 272-283, 2018 | 91 | 2018 |
| Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review AJN Raymakers, J Mayo, S Lam, JM FitzGerald, DGT Whitehurst, LD Lynd Applied health economics and health policy 14, 409-418, 2016 | 85 | 2016 |
| Cost utility of early versus delayed laparoscopic cholecystectomy for acute cholecystitis A Johner, A Raymakers, SM Wiseman Surgical Endoscopy, 1-7, 2012 | 85 | 2012 |
| The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study AJN Raymakers, M Sadatsafavi, DD Sin, MA De Vera, LD Lynd Chest 152 (3), 486-493, 2017 | 57 | 2017 |
| High cost of chimeric antigen receptor T-cells: challenges and solutions ERS Cliff, AH Kelkar, DA Russler-Germain, FA Tessema, AJN Raymakers, ... American Society of Clinical Oncology Educational Book 43, e397912, 2023 | 51 | 2023 |
| The effectiveness of physiologically based early warning or track and trigger systems after triage in adult patients presenting to emergency departments: a systematic review F Wuytack, P Meskell, A Conway, F McDaid, N Santesso, FG Hickey, ... BMC emergency medicine 17, 1-14, 2017 | 51 | 2017 |
| Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study AJN Raymakers, M Sadatsafavi, DD Sin, JM FitzGerald, CA Marra, ... European Respiratory Journal 53 (6), 2019 | 50 | 2019 |
| Economic and humanistic burden of external genital warts AJN Raymakers, M Sadatsafavi, F Marra, CA Marra Pharmacoeconomics 30, 1-16, 2012 | 46 | 2012 |
| Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review AJN Raymakers, N McCormick, CA Marra, JM Fitzgerald, D Sin, LD Lynd Respirology 22 (1), 61-70, 2017 | 38 | 2017 |
| Understanding cancer survivors’ reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior H McTaggart‐Cowan, C Bentley, A Raymakers, R Metcalfe, P Hawley, ... Cancer medicine 10 (1), 396-404, 2021 | 35 | 2021 |
| Reducing potentially inappropriate prescribing for older people in primary care: cost-effectiveness of the OPTI-SCRIPT intervention P Gillespie, B Clyne, A Raymakers, T Fahey, CM Hughes, SM Smith International Journal of Technology Assessment in Health Care, 1-10, 2017 | 31 | 2017 |
| Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study K Jenei, AJN Raymakers, A Bayle, K Berger-Thürmel, A Cherla, K Honda, ... The lancet oncology 24 (6), 624-635, 2023 | 30 | 2023 |
| Factors influencing health-related quality of life in patients with Type 1 diabetes AJN Raymakers, P Gillespie, MC O’Hara, MD Griffin, SF Dinneen Health and quality of life outcomes 16, 1-5, 2018 | 26 | 2018 |
| Diagnostic strategies incorporating computed tomography angiography for pulmonary embolism: a systematic review of cost-effectiveness analyses AJN Raymakers, J Mayo, CA Marra, M FitzGerald Journal of thoracic imaging 29 (4), 209-216, 2014 | 23 | 2014 |
| Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review AJN Raymakers, DA Regier, SJ Peacock Cancer 126 (1), 148-155, 2020 | 22 | 2020 |
| Defining a core data set for the economic evaluation of precision oncology S Pollard, D Weymann, B Chan, M Ehman, S Wordsworth, J Buchanan, ... Value in Health 25 (8), 1371-1380, 2022 | 18 | 2022 |
| Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study AJN Raymakers, DD Sin, M Sadatsafavi, JM FitzGerald, CA Marra, ... Respiratory Research 21 (1), 1-11, 2020 | 18 | 2020 |
| Modelling uncertainty in survival and cost-effectiveness is vital in the era of gene therapies: the case of axicabtagene ciloleucel AJN Raymakers, DA Regier, SJ Peacock Health Policy and Technology 8 (2), 103-104, 2019 | 15 | 2019 |
| Quality of end-of-life cancer care in Canada: a 12-year retrospective analysis of three provinces’ administrative health care data evaluating changes over time AF Khan, H Seow, R Sutradhar, S Peacock, KKW Chan, F Burge, ... Current Oncology 28 (6), 4673-4685, 2021 | 13 | 2021 |
Larry LyndProfessor, Epidemiology, University of British ColumbiaPotvrđena adresa e-pošte na ubc.ca
